FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Cureus2024; 16(11); e73040; doi: 10.7759/cureus.73040

Gold-Induced Cytokine (GOLDIC) for the Management of Knee Osteoarthritis: A Systematic Review.

Abstract: Gold-induced cytokine (GOLDIC) is a novel orthobiologic approach utilizing gold particles to produce a serum rich in immunoregulating cytokines and growth factors, which is being explored for its potential in tissue regeneration and treating musculoskeletal issues like knee osteoarthritis (OA). This study aims to review its mechanism of action along with the outcomes of , preclinical, and clinical studies, with a secondary focus on documenting clinical trials related to its use in OA of the knee. A systematic search was conducted in four databases (Embase, Scopus, PubMed, Web of Science) for studies on GOLDIC therapy for knee OA, using specific keywords related to knee anatomy and OA.  studies demonstrated that gold-containing compounds reduce nitric oxide production in chondrocytes, mitigating catabolic processes. Pre-clinical trials in horses with lameness showed significant symptom improvement. Clinical studies reported substantial improvements in pain, function, and joint homeostasis, with reduced synovial effusion and cytokine modulation following GOLDIC therapy. GOLDIC therapy, in addition to orthopedic indications such as for the management of OA of the knee, has also been investigated in non-orthopedic settings with early promising results. However, more research is needed to fully understand its mechanism of action and establish its clinical utility.
Copyright © 2024, Aratikatla et al.
Get Full Text
Publication Date: 2024-11-05 PubMed ID: 39640134PubMed Central: PMC11618964DOI: 10.7759/cureus.73040Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study reviews the use of Gold-Induced Cytokine (GOLDIC) therapy, a new treatment using gold particles to enrich serum with cytokines and growth factors, for managing knee osteoarthritis (OA).
  • The research examines how GOLDIC works, summarizes preclinical and clinical outcomes, and identifies ongoing clinical trials related to knee OA treatment.

Introduction to GOLDIC Therapy

  • GOLDIC is an innovative orthobiologic treatment leveraging gold particles to stimulate the production of immunoregulatory cytokines and growth factors in the patient’s serum.
  • These bioactive components are thought to enhance tissue regeneration and modulate inflammation, potentially benefiting musculoskeletal conditions such as knee osteoarthritis.
  • The therapy is designed to reduce inflammation and promote joint repair, thereby improving symptoms related to joint degeneration.

Objectives and Methods of the Study

  • The primary objective was to comprehensively review existing literature on the mechanism and effectiveness of GOLDIC therapy in knee OA.
  • Secondary objective involved cataloging clinical trials exploring GOLDIC for knee OA management.
  • A systematic literature search was performed across Embase, Scopus, PubMed, and Web of Science databases using carefully selected keywords focused on knee anatomy and osteoarthritis.
  • Both preclinical (laboratory and animal studies) and clinical studies were included to provide a broad evidence base.

Mechanism of Action

  • Gold compounds in GOLDIC reduce nitric oxide production by chondrocytes, the cells responsible for cartilage maintenance.
  • Lower nitric oxide levels help mitigate catabolic (destructive) processes within the joint cartilage, slowing degeneration.
  • The serum enriched with cytokines and growth factors modulates the inflammatory environment in the joint, promoting healing and reducing symptoms.

Preclinical Evidence

  • Animal studies, including trials in horses with lameness, demonstrated significant improvement in symptoms following GOLDIC treatment.
  • These studies helped establish safety and potential efficacy, supporting progression to human clinical trials.

Clinical Evidence

  • Clinical studies reported notable improvements in key outcome measures such as pain relief, joint function, and overall joint homeostasis after GOLDIC therapy.
  • Reduction in synovial fluid effusion (joint swelling) was documented, suggesting an anti-inflammatory effect.
  • Modulation of cytokine levels post-treatment indicated GOLDIC influences immune responses within the affected knee joint.
  • These findings suggest that GOLDIC may be an effective non-surgical option for managing symptoms and progression of knee osteoarthritis.

Additional Applications and Future Directions

  • Beyond orthopedics, GOLDIC has been explored in other medical fields with promising early results, indicating a potential broad utility of this therapy.
  • Despite encouraging data, the exact biochemical and cellular mechanisms of GOLDIC remain incompletely understood.
  • Further research, including larger randomized controlled trials and mechanistic studies, is necessary to establish optimal protocols, long-term efficacy, and safety.
  • Future investigations may refine patient selection criteria and help integrate GOLDIC into standard OA treatment regimens.

Conclusion

  • GOLDIC represents a promising new orthobiologic therapy for knee osteoarthritis by utilizing gold particle-induced cytokine production to reduce inflammation and promote joint healing.
  • Evidence from early studies supports its potential benefits in symptom improvement and cartilage preservation, though more in-depth studies are needed.
  • Clinical use of GOLDIC could expand if ongoing and future research confirms its efficacy and clarifies its mechanisms.

Cite This Article

APA
Aratikatla A, Viswanathan VK, Ghandour S, Jain VK, Gupta A. (2024). Gold-Induced Cytokine (GOLDIC) for the Management of Knee Osteoarthritis: A Systematic Review. Cureus, 16(11), e73040. https://doi.org/10.7759/cureus.73040

Publication

Cureus
ISSN: 2168-8184
NlmUniqueID: 101596737
Country: United States
Language: English
Volume: 16
Issue: 11
Pages: e73040
PII: e73040

Researcher Affiliations

Aratikatla, Adarsh
  • Medical School, The Royal College of Surgeons in Ireland, Dublin, IRL.
Viswanathan, Vibhu Krishnan
  • Department of Orthopedics, Dr Rela Institute and Medical Center, Chennai, IND.
Ghandour, Samir
  • Foot and Ankle Research and Innovation Laboratory, Harvard Medical School, Boston, USA.
Jain, Vijay Kumar
  • Department of Orthopedics, Atal Bihari Vajpayee Institute of Medical Sciences, Dr Ram Manohar Lohia Hospital, New Delhi, IND.
Gupta, Ashim
  • Department of Regenerative Medicine, Future Biologics, Lawrenceville, USA.

Conflict of Interest Statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

This article includes 44 references
  1. Jeyaraman M, Jeyaraman N, Ram PR, Venkatasalam R, Yadav S. GOLD-Induced Cytokine (GOLDIC): a game-changer orthobiologic in regenerative medicine.. Cureus 2023;15:0.
    pmc: PMC10582645pubmed: 37859872
  2. Jackson P, Murrell WD. Biologics and regenerative medicine- what's new, what’s next.. J Postgrad Med Educ Res 2018;52.
  3. Godek P, Szczepanowska-Wolowiec B, Golicki D. GOLDIC therapy in degenerative lumbar spinal stenosis: randomized, controlled trial.. Regen Med 2022;17:709–718.
    pubmed: 35899459
  4. Schneider U, Veith G. First results on the outcome of gold-induced, autologous-conditioned serum (GOLDIC) in the treatment of different lameness-associated equine diseases.. J Cell Sci Ther 2014;5.
  5. Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez-Almazor ME. Injectable gold for rheumatoid arthritis.. Cochrane Database Syst Rev 2000;1997:0.
    pmc: PMC7045741pubmed: 10796386
  6. Schneider U, Wallich R, Felmet G, Murrell WD. Gold-induced autologous cytokine treatment in Achilles tendinopathy. Muscle and Tendon Injuries Vol. 10. Berlin, Heidelberg: Springer; 2017; pp. 411–419.
  7. Tulpule S, Jeyaraman M, Jayakumar T, Jeyaraman N, Bapat A, Yadav S. Gold-Induced Cytokine (GOLDIC®) therapy in the management of knee osteoarthritis: an observational study.. Cureus 2023;15:0.
    pmc: PMC10613552pubmed: 37908900
  8. Schneider U, Kumar A, Murrell W, Ezekwesili A, Yurdi NA, Maffulli N. Intra-articular gold induced cytokine (GOLDIC®) injection therapy in patients with osteoarthritis of knee joint: a clinical study.. Int Orthop 2021;45:497–507.
    pubmed: 33404700
  9. Feldt J, Donaubauer AJ, Welss J, Schneider U, Gaipl US, Paulsen F. Anti-inflammatory effects of an autologous gold-based serum therapy in osteoarthritis patients.. Sci Rep 2022;12:3560.
    pmc: PMC8894375pubmed: 35241691
  10. Lim WL, Liau LL, Ng MH, Chowdhury SR, Law JX. Current progress in tendon and ligament tissue engineering.. Tissue Eng Regen Med 2019;16:549–571.
    pmc: PMC6879704pubmed: 31824819
  11. Vuolteenaho K, Kujala P, Moilanen T, Moilanen E. Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage.. Scand J Rheumatol 2005;34:475–479.
    pubmed: 16393772
  12. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions.. Cell Mol Life Sci 2004;61:2614–2623.
    pmc: PMC11924436pubmed: 15526166
  13. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis.. Crit Care Med 1997;25:594–598.
    pubmed: 9142022
  14. Tang JZ, Nie MJ, Zhao JZ, Zhang GC, Zhang Q, Wang B. Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis.. J Orthop Surg Res 2020;15:403.
    pmc: PMC7488405pubmed: 32912243
  15. Page MJ, McKenzie JE, Bossuyt PM. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.. BMJ 2021;372:0.
    pmc: PMC8008539pubmed: 33781348
  16. Pithadia P, Tulpule S, Patel CR. Gold-Induced Cytokine (Goldic®) - a promising treatment in patients with Grade 4 knee osteoarthritis: a case study.. Int J Clin Case Rep Rev 2023.
  17. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations.. Arthritis Rheum 2006;54:226–229.
    pubmed: 16385518
  18. Healy WL, Della Valle CJ, Iorio R, Berend KR, Cushner FD, Dalury DF, Lonner JH. Complications of total knee arthroplasty: standardized list and definitions of the Knee Society.. Clin Orthop Relat Res 2013;471:215–220.
    pmc: PMC3528930pubmed: 22810157
  19. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis.. Ann Rheum Dis 1957;16:494–502.
    pmc: PMC1006995pubmed: 13498604
  20. Hochberg MC, Altman RD, Brandt KD. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee.. Arthritis Rheum 1995;38:1541–1546.
    pubmed: 7488273
  21. Navarro-Sarabia F, Coronel P, Collantes E. A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project.. Ann Rheum Dis 2011;70:1957–1962.
    pmc: PMC3184238pubmed: 21852252
  22. Creamer P. Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?. Ann Rheum Dis 1997;56:634–636.
    pmc: PMC1752292pubmed: 9462163
  23. Indrawattana N, Chen G, Tadokoro M. Growth factor combination for chondrogenic induction from human mesenchymal stem cell.. Biochem Biophys Res Commun 2004;320:914–919.
    pubmed: 15240135
  24. McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression.. J Orthop Res 2009;27:1033–1042.
    pubmed: 19170097
  25. Gupta A, Jain VK. Autologous peripheral blood-derived orthobiologics: different types and their effectiveness in managing knee osteoarthritis.. World J Orthop 2024;15:400–403.
    pmc: PMC11145965pubmed: 38835681
  26. Gupta A, Jain V. Autologous conditioned plasma (ACP) and osteoarthritis of the knee: a review of current clinical evidence.. Cureus 2024;16:0.
    pmc: PMC10879647pubmed: 38384614
  27. Gupta A, Aratikatla A. Hyperacute serum and knee osteoarthritis.. Cureus 2024;16:0.
    pmc: PMC10899007pubmed: 38420081
  28. Gupta A. Autologous protein solution (APS) and osteoarthritis of the knee: a scoping review of current clinical evidence.. Cureus 2024;16:0.
    pmc: PMC10915583pubmed: 38449974
  29. Gupta A, Maffulli N. Growth factor concentrate (GFC) for the management of osteoarthritis of the knee: a systematic review.. Indian J Orthop 2024;58:829–834.
    pmc: PMC11208381pubmed: 38948375
  30. Gupta A, Maffulli N. Platelet lysate and osteoarthritis of the knee: a review of current clinical evidence.. Pain Ther 2024.
    pmc: PMC11543954pubmed: 39340713
  31. Gupta A, Potty AG, Gupta A, Potty A. Autologous peripheral blood-derived orthobiologics for the management of hip osteoarthritis: a systematic review of current clinical evidence.. Cureus 2024;16:0.
    pmc: PMC11539075pubmed: 39507183
  32. Jeyaraman N, Jeyaraman M, Ramasubramanian S, Yadav S, Balaji S, Patro BP, Gupta A. Autologous conditioned serum in knee osteoarthritis: a systematic review of current clinical evidence.. Cureus 2024;16:0.
    pmc: PMC11461807pubmed: 39385904
  33. Gupta A. Exosomes for the management of low back pain: a review of current clinical evidence.. Cureus 2024;16:0.
    pmc: PMC11068073pubmed: 38707134
  34. Zhao Y, Li Y, Qu R. Cortistatin binds to TNF-α receptors and protects against osteoarthritis.. EBioMedicine 2019;41:556–570.
    pmc: PMC6443028pubmed: 30826358
  35. Qi C, Shan Y, Wang J, Ding F, Zhao D, Yang T, Jiang Y. Circulating T helper 9 cells and increased serum interleukin-9 levels in patients with knee osteoarthritis.. Clin Exp Pharmacol Physiol 2016;43:528–534.
    pubmed: 26926842
  36. Li GH, Arora PD, Chen Y, McCulloch CA, Liu P. Multifunctional roles of gelsolin in health and diseases.. Med Res Rev 2012;32:999–1025.
    pubmed: 22886630
  37. Piktel E, Levental I, Durnaś B, Janmey PA, Bucki R. Plasma gelsolin: indicator of inflammation and its potential as a diagnostic tool and therapeutic target.. Int J Mol Sci 2018;19:2516.
    pmc: PMC6164782pubmed: 30149613
  38. Okano T, Mera H, Itokazu M, Okabe T, Koike T, Nakamura H, Wakitani S. Systemic administration of granulocyte colony-stimulating factor for osteochondral defect repair in a rat experimental model.. Cartilage 2014;5:107–113.
    pmc: PMC4297080pubmed: 26069690
  39. Hanly JG, Hassan J, Whelan A, Feighery C, Bresnihan B. Effects of gold therapy on the synthesis and quantity of serum and synovial fluid IgM, IgG, and IgA rheumatoid factors in rheumatoid arthritis patients.. Arthritis Rheum 1986 29:480–487.
    pubmed: 3707625
  40. DiNubile MJ. Plasma gelsolin as a biomarker of inflammation.. Arthritis Res Ther 2008;10:124.
    pmc: PMC2656232pubmed: 19105851
  41. Melo SN, Ezekwesili A, Yurdi NA, Murrell WD, Maffulli N. Gold-Induced Cytokine (GOLDIC(®)) injection therapy in patient with plantar fasciosis: a case report.. Indian J Orthop 2020;54:348–351.
    pmc: PMC7205939pubmed: 32399155
  42. Cordes F, Curaj A, Simsekyilmaz S, Schneider U, Liehn EA. Anti-inflammatory gold-induced autologous cytokines treatment triggers heart failure after myocardial infarction.. Discoveries (Craiova) 2017;5:0.
    pmc: PMC7159843pubmed: 32309598
  43. Schneider U, Hollands P. Intravenous gold-induced autologous serum injection therapy (Go ACT®) as a new treatment for seasonal pollen-based allergies.. Eur Rev Med Pharmacol Sci 2021;25:4121–4127.
    pubmed: 34156692
  44. Schneider U, Hollands P, Schicht M, Paulsen F. Post Covid19 syndrome treatment using autologous gold-activated serum: a preliminary clinical study.. Ann Case Rep 2022;7.

Citations

This article has been cited 2 times.
  1. Huang R, Lu J, Yang X, Sheng G, Qin F, Yang X. Molecular mechanism of the effect of BixiezelanYin on knee osteoarthritis based on network pharmacology and molecular docking.. Medicine (Baltimore) 2025 Feb 7;104(6):e41459.
    doi: 10.1097/MD.0000000000041459pubmed: 39928767google scholar: lookup
  2. Gupta A, Migliorini F, Bardazzi T, Maffulli N. Autologous Peripheral Blood-Derived Orthobiologics for the Management of Elbow Disorders: A Review of Current Clinical Evidence.. Pain Ther 2025 Apr;14(2):497-511.
    doi: 10.1007/s40122-025-00707-9pubmed: 39878915google scholar: lookup
Subscribe to our newsletter
Join 100,280 horse owners like you who receive our email updates on horse health and nutrition.